NanoViricides, Inc. said that the ultra-broad antiviral activity spectrum of NV-387 includes activity against orthopoxvirus family (Smallpox/Mpox), with both inhalation and skin abrasion (sexual) modes of infection acquisition. Ectromelia virus infection of mice is a model for Smallpox infection in humans, and also serves as a surrogate for MPox infection in humans. All three viruses belong to the orthopoxvirus family.

NanoViricides reports that in a lethal animal model of lung infection by Ectromelia virus, oral dosing with NV-387 led to an increase in lifespan of mice that was comparable to oral treatment with tecovirimat (TPOXX, the approved drug against Smallpox. This lung infection study substantiates the results of the previously reported intradigital footpad infection study that: (i) NV-387 has comparable antiviral activity as tecovirimat, and (ii) NV-387 plus tecovirimat has much stronger antiviral activity than either drug alone. The company has completed a lethality animal study wherein animals were infected with ectromelia virus into the lungs directly.

In this study, the company found that NV-387 alone treated animals survived 15 days, tecovirimat alone treated animals survived 16 days, and NV-387 plus tec Covirimat treated animals survived 19 days, whereas vehicle-treated animals died in 8 days. This lung-infection study emulates infection from aerosolized dispersion of the virus, as may be expected in aiot errorism scenario.ecovirimat has a low barrier of escape; a single mutation in one protein can enable the virus to escape this drug, adding to the significance of additional smallpox drug development. Therefore the company believe that NV-387 is a viable clinical candidate to be developed by itself for the treatment ofpoxvirus infections under the US FDA " Animal Rule".

In addition, the company believe that the combination of NV-387 andtecovirimat could reduce the potential for escape resistant generation against tecovirimat. The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. NV-387 has successfully completed a Phase 1a/1b clinical trial in which no adverse events were reported indicating excellent safety.

Karveer Meditech Pvt. Ltd., licensee and collaborator in India sponsored the drug for this clinical trial. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

NanoViricides' platform technology and programs are based on the TheraCour®? nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development.

Further, there can be no assurance At this time that successful results against coronavirus in lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors.

Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of product candidates; ability to seek and obtain regulatory approvals, including with respect to the indications the successful commercialization of product candidates; and market acceptance of products.